A pilot trial of prophylactic defibrotide to prevent serious thrombotic microangiopathy in high-risk pediatric patients.
Christine S HighamKristin A ShimanoAlexis MeltonSandhya KharbandaJulia ChuJasmeen DaraLena E WinestoneMichelle L HermistonJames N HuangChristopher C DvorakPublished in: Pediatric blood & cancer (2022)
Our study provides evidence that defibrotide prophylaxis is feasible in pediatric patients undergoing HSCT at high risk for TA-TMA and preliminary data indicating that defibrotide may reduce the risk of TA-TMA.